Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329294 | 0.83 | CA2 (0.71) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL329449 | 0.82 | CA2 (0.69) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL3137645 | 0.80 | CA2 (0.46) | CA2AKR1B1CCR2 | |
| SCHEMBL329450 | 0.80 | CA2 (0.67) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL12157405 | 0.80 | CA2 (0.67) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL25119616 | 0.80 | CA2 (0.67) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL792780 | 0.80 | CA2 (1.00) | CA2CA9CA1 | |
| SCHEMBL7467720 | 0.79 | CA2 (0.61) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL6955915 | 0.79 | CA2 (0.48) | CA2AKR1B1CCR2CYP2A6BCL2L1 | |
| SCHEMBL7341029 | 0.79 | CA2 (0.48) | CA2AKR1B1CCR2CYP2A6BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265858-B1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | DU PONT (US) | 2004-05-19 | — | — | EP | claimed |
| US-6667421-B2 | Hydrogenating an aryl sulfonyl chloride with hydrogen in a solvent in the presence of a palladium catalyst and a base whose conjugate acid pka is >/=2 | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-23 | — | — | US | claimed |
| US-20030055290-A1 | Hydrogen reduction of sulfonyl chlorides to thiols | THE TEXAS A&M UNIVERSITY SYSTEM | 2003-03-20 | — | — | US | claimed |
| EP-1265858-A1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001066517-A1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| CN-116874532-A | High-efficiency preparation method and application of 4-hydrobenzo [1,2] azaphosphine-3-ketone-1-oxide series compound | 浙大城市学院 | 2023-10-13 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5202339-A | Hypoglycemic, hypolipedemic agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5004751-A | Antidiabetic agents; aldoe reductase inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4914099-A | TREATMENT OR PREVENTION OF DIABETIC COMPLICATIONS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| WO-1990002126-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355827-A2 | Hydantoin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989001934-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-09 | — | — | WO | disclosed |
| EP-0305947-A1 | Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | CA2 3672/4885AKR1B1 2894/4885CCR2 1539/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | CA2 740/4885AKR1B1 2008/4885CCR2 2217/4885 |
| US-20030055290-A1 | Hydrogen reduction of sulfonyl chlorides to thiols | TST, IAPP, CBS | CA2 2286/4885AKR1B1 617/4885CCR2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.